SPRO - Spero Therapeutics, Inc.
0.578
-0.012 -2.076%
Share volume: 57,128
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$0.59
-0.01
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-15-2024 | 08-05-2024 | 11-14-2024 | 03-27-2025 | |
| Total revenue | 9.267 M | 10.197 M | 13.469 M | 15.044 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 9.267 M | 10.197 M | 13.469 M | 15.044 M | |
| 10.04% | 32.09% | 11.69% | |||
| Operating expenses | 23.249 M | 29.258 M | 32.062 M | 35.892 M | |
| Selling general and admin | 5.917 M | 5.533 M | 5.198 M | 7.056 M | |
| Research and development | 17.332 M | 23.725 M | 26.864 M | 28.836 M | |
| Total expenses | 23.249 M | 29.258 M | 32.062 M | 36.769 M | |
| 25.85% | 9.58% | 14.68% | |||
| Operating income | -13.982 M | -19.061 M | -18.593 M | -21.725 M | |
| Ebit | -13.996 M | -19.060 M | -18.619 M | -21.626 M | |
| Pretax income | -12.669 M | -17.862 M | -17.437 M | -20.598 M | |
| 40.99% | -2.38% | 18.13% | |||
| Income tax | 0.000 | 0.000 | -290.000 K | 290.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -12.669 M | -17.862 M | -17.147 M | -20.888 M | |
| -40.99% | 4.00% | -21.82% |
